StockData
Codexis, Inc. logo

Codexis, Inc. (CDXS) company profile

CDXSNasdaqIndustrial Organic ChemicalsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/301% below fair value
$1.07+0.01 (+0.94%)

Close on Nov 17, 2026Market cap $117.17MP/E –Yield –

About Codexis

Industrial Organic Chemicals, SIC 2860

Codexis, Inc. discovers, engineers, and supplies specialized enzymes and proteins to optimize the manufacturing of biopharmaceutical therapeutics. The company operates through two primary areas: its small molecule biocatalysis business and its ECO Synthesis platform. In biocatalysis, it designs custom enzymes that act as biocatalysts to improve synthesis efficiency, product purity, and yield for small-molecule drugs. Through its ECO Synthesis platform, the company provides enzymatic synthesis tools and contract process development services to support the production of RNA interference therapies, including small interfering RNA. Its customers include global pharmaceutical developers, biotechnology firms, and contract development and manufacturing organizations.

The company is headquartered in Redwood City, California, where it conducts research, development, and small-scale manufacturing at its innovation laboratory. Codexis also holds a facility lease in Hayward, California. Its enzyme products support eighteen commercially approved drugs and fifteen clinical-stage candidates. External commercial manufacturing takes place through third-party partners situated in Austria, Italy, and the United Kingdom.

Summary of the business section of Codexis's latest annual report, written by StockData.

Company profile

Company

Legal name
Codexis, Inc.
Founded
2002
Headquarters
Redwood City, CA
Address
200 Penobscot Drive 94063
Phone
(650) 421-8100
Employees
146, Dec 31, 2025
Industry
Industrial Organic Chemicals
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, CA

Stock & identifiers

Ticker
CDXS
Exchange
Nasdaq
IPO date
Apr 22, 2010
Shares outstanding
110M, Aug 6, 2026
Public float
$133.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1200375
CUSIP
192005106
ISIN
US1920051067
FIGI
BBG000RN0GZ5
Share class FIGI
BBG001SV4129
LEI
549300KGLM6CDPTVSE20
EIN
71-0872999

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alison MoorePresident and CEO, Director244,171
Georgia ErbezSee Remarks60,475
Stefan LutzChief Scientific Officer130,421
Kevin NorrettChief Operating Officer177,327
Vre Raymond DeDirector83,723
Cynthia CollinsDirector112,157
Esther MartinboroughDirector129,036
Christos RichardsDirector85,133
Rahul SinghviDirector137,052
H. Stewart ParkerDirector143,583
Stephen George DillyDirector727,053
David V. SmithDirector194,275
Dennis P. WolfDirector138,951

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Alison Moore
$2.32M$920.92K$1.27M$35–
FY2025
Stephen Dilly
$2.19M-$789.80K$1.27M$35–
FY2024$3.47M$6.21M$1.31M$102–
FY2023$3.12M$1.23M$1.94M$65–
FY2022
John J.Nicols
$3.42M-$3.86M$1.93M$15–
FY2022
John Nicols
$3.42M-$3.86M$1.93M$15–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Alison Moore
President and Chief Executive Officer
$524.73K$255.99K$1.07M$463.13K$14.21K$2.32M+111%
Georgia Erbez
Chief Financial Officer and Chief Business Officer
$507.42K$117.44K$487.52K$237.50K$1.04K$1.35M+45%
Stefan Lutz
Chief Scientific Officer
$481.57K$76.48K$317.46K$232.75K$14.84K$1.12M–
Stephen G. Dilly
Executive Chair of the Board of Directors and former President and Chief Executive Officer
$758.90K$374.95K$489.69K$521.05K$50.01K$2.19M-37%
Kevin Norrett
Former Chief Operating Officer
$501.30K$57.31K$10.58K$250.00K$514.72K$1.33M-12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 146 full-time employees and part-time employees worldwide.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?